Minimal Residual Disease Testing Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Minimal Residual Disease Testing Market

Minimal Residual Disease Testing Market Growth by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecasts to 2027

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 8516 Dec, 2022, by marketsandmarkets.com

The global minimal residual disease testing market boasts a total value of $1.2 Billion in 2022 and is projected to register a growth rate of 14.0% to reach a value of $2.3 billion by 2027. Market is driven by the rising incidence and prevalence of cancer and hematological malignancies.

Minimal Residual Disease Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Minimal Residual Disease Testing Market Dynamics

Drivers: Rising incidence of hematological malignancies

Over the years, the incidence of hematologic cancer has increased significantly, which includes leukemia and lymphoma. According to the Leukemia & Lymphoma Society 2020-2021, an estimated 1,519,907 people in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Also, the rising geriatric population across the globe is also a key factor supporting the increasing incidence of hematologic malignancies, as this population segment is more prone to various chronic diseases. Such cancer patients require continuous monitoring of disease during treatment. Also, the monitoring of minimal residual diseases (MRD) has become a routine clinical practice post-cancer treatment. As a result, the preference for minimal residual disease testing will likely rise in the forecast period, proportional to the growth in cancer prevalence.

Restraints: Complex regulatory framework and high cost of minimal residual disease testing kits

Regulatory and legal requirements applied to minimal residual tests are becoming more stringent.  The FDA requirements and the time required to obtain premarket approval have increased, particularly regarding 510(k) applications with the FDA facing challenges when there is no standardized method for an analyte. On the other hand, the implementation of minimal residual disease testing products in diagnostic laboratories requires high capital investments. For instance, the cost of advanced minimal residual disease testing products varies between USD 20,000 and USD 50,000. In developing countries such as India and Brazil, owing to budget constraints, small and medium-sized organizations and academic laboratories cannot afford advanced and high-priced MRD kits. These factors restrain the market growth.

Opportunities: Growth opportunities in minimal residual disease testing in emerging countries

Developing economies such as India, South Korea, Brazil, Turkey, Russia, and South Africa are expected to offer potential growth opportunities for major players operating in the minimal residual disease testing market. This can be attributed to the rising geriatric population, the growing incidence of hematologic cancers, rising health expenditure per capita, and improving healthcare infrastructure. In addition to the factors mentioned above, the Asia Pacific region has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

Challenges: Unclear reimbursement scenario and policies for patients

The procedure of paying for pricey molecular testing and the knowledge of the several specialists needed to interpret test results and create treatment programmes are convoluted and even. This is particularly problematic with more expensive modern methods like liquid biopsy which also includes testing minimal residual disease. The price of molecular testing services is frequently unknown to doctors, pathologists and patients until they are paid or billed. This results in a confusion between the patients and the providers.

Additionally, payers’s biomarker coverage policies have complex organizational structures that are quite challenging to comprehend. While some only pay for the most fundamental testsor those related to certain clinical disordersand genes, others pay for a wide variety of testing. Due to significant variety, it is also very difficult to evaluate and keep track of different coverage policies.

The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. The main elements contributing to the substantial proportion of this segment are the device’s simplicity of use, the accessibility of test kits and a better degree of sensitivity.

Hematological Malignancies applications segment accounted for the highest CAGR

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Leukemia, lymphoma and their various sub-types are becoming very common, and people are becoming more aware of the importance of ongoing patient monitoring, all of which are factors supporting the expansion of this market.

Hospitals & specialty clinics segment to dominate the minimal residual disease testing market

Based on end users, the minimal residual disease testing market has been segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2021, the hospitals & specialty clinics segment accounted for the largest share of this market, while diagnostic laboratories are growing at the highest rate. The presence of cutting-edge diagnostic tools and qualified specialist to conduct these tests is what accounts for the big share of this market.

North America is the largest regional market for liquid biopsy

Growth in the developed markets of North America is primarily driven by The large share of this regional segment can be attributed to the significant increase of leukemia and lymphoma, highly developed healthcare culture in the US and Canada, the presence of numerous top national clinical laboratories, and the easy accessibility to cutting-edge technology.

Minimal Residual Disease Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some of the key players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US).

Minimal Residual Disease Testing Market Scope

Report Metrics

Details

Market Size value 2027

USD 2.3 billion

Growth Rate

14.0% CAGR

Largest Market

North America

Market Dynamics

Drivers, Opportunities, Restraints & Challenges

Largest Share Segments
  • The Pcr Segment Accounted for The Highest Growth Rate
  • Hematological Malignancies Applications Segment Accounted for the Highest Cagr
  • Hospitals & Specialty Clinics Segment to Dominate The Market

Forecasts up to

2027

Market Segmentation

Technology, Application, End User and Region

Minimal Residual Disease Testing Market Growth Drivers

 Rising incidence of hematological malignancies

Minimal Residual Disease Testing Market Growth Opportunities

 Growth opportunities in minimal residual disease testing in emerging countries

Report Highlights
  • Updated financial information/ product portfolio of players
  • Updated market developments of profiled players

Geographies Covered

North America, Europe, APAC, MEA, and Latin America

This report categorizes the minimal residual disease testing market into the following segments and subsegments:

By Technology

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other Technologies

By Application

  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Solid Tumors
  • Other Applications

By End User

  • Hospitals and Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In February 2019, Bio-Rad Laboratories, Inc. (US) announced the launch of the first FDA-cleared digital PCR system and test for monitoring chronic myeloid leukemia treatment response.In May 2022, QIAGEN N.V. (Netherlands) launched the therascreen EGFR Plus RGQ PCR Kit, a new in vitro diagnostic test for sensitive EGFR mutation analysis.
  • In August 2022, Roche launched the Digital LightCycler System, the company’s first digital polymerase chain reaction (PCR) system. This next-generation system detects diseases and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
  • In February 2021, Guardant launched the Guardant Reveal Liquid Biopsy Test for residual disease and recurrence monitoring in patients with early-stage colorectal cancer.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

 

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 25)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKETS COVERED 
           1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE 
    2.6 STUDY ASSUMPTIONS 
    2.7 GROWTH RATE ASSUMPTIONS 
    2.8 RISK ASSESSMENT 
           2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 41)
    FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2022 VS. 2027 (USD MILLION)
    FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2022 VS. 2027 (USD MILLION)
    FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2022 VS. 2027 (USD MILLION)
    FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION,  2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 44)
    4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW 
          FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET
    4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE,  BY TECHNOLOGY, 2022 VS. 2027 
          FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027
    4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE,  BY APPLICATION, 2022 VS. 2027 
          FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET  IN 2027
    4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE,  BY END USER, 2022 VS. 2027 
          FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
    4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET:  GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 47)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of hematological malignancies
                                TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
                    5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
                    5.2.1.3 Increasing cancer awareness initiatives by global health organizations
           5.2.2 RESTRAINTS
                    5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests
                    5.2.2.2 High cost of minimal residual disease testing kits
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries
                                TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
           5.2.4 CHALLENGES
                    5.2.4.1 Unclear reimbursement scenario and policies for patients
    5.3 PRICING ANALYSIS 
          TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)
    5.4 PATENT ANALYSIS 
          FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
           5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET ANALYSIS 
          FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS
          TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REGULATORY ANALYSIS 
          TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                                TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.9.3.2 Japan
                                TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
                     TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY,  2017–2021 (USD MILLION)
                     TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY,  2017–2021 (USD MILLION)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 
           TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS
                     FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS
                     TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
           5.14.2 BUYING CRITERIA
                     FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
                     TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
    5.15 CASE STUDY ANALYSIS 
 
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY (Page No. - 71)
    6.1 INTRODUCTION 
          TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
    6.2 POLYMERASE CHAIN REACTION 
           6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
                    TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION,  2020–2027 (USD MILLION)
    6.3 NEXT-GENERATION SEQUENCING 
           6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET
                    TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION,  2020–2027 (USD MILLION)
    6.4 FLOW CYTOMETRY 
           6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH
                    TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
    6.5 OTHER TECHNOLOGIES 
          TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
 
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION (Page No. - 77)
    7.1 INTRODUCTION 
          TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
    7.2 HEMATOLOGICAL MALIGNANCIES 
          TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION)
           7.2.1 LEUKEMIA
                    TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE,  2020–2027 (USD MILLION)
                    7.2.1.1 Myeloid leukemia
                               7.2.1.1.1 High prevalence of AML in adults to support growth
                                              TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
                    7.2.1.2 Lymphocytic leukemia
                               7.2.1.2.1 High incidence of ALL in children to drive market
                                              TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA,  BY REGION, 2020–2027 (USD MILLION)
                    7.2.1.3 Other leukemias
                                 TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
           7.2.2 LYMPHOMA
                    TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE,  2020–2027 (USD MILLION)
                    7.2.2.1 Non-Hodgkin lymphoma
                               7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
                                              TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA,  BY REGION, 2020–2027 (USD MILLION)
                    7.2.2.2 Hodgkin lymphoma
                               7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing
                                              TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
    7.3 SOLID TUMORS 
           7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
                    TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION,  2020–2027 (USD MILLION)
    7.4 OTHER APPLICATIONS 
          TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
 
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER (Page No. - 87)
    8.1 INTRODUCTION 
          TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
    8.2 HOSPITALS & SPECIALTY CLINICS 
           8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
                    TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS,  BY REGION, 2020–2027 (USD MILLION)
    8.3 DIAGNOSTIC LABORATORIES 
           8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
                    TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES,  BY REGION, 2020–2027 (USD MILLION)
    8.4 ACADEMIC & RESEARCH INSTITUTES 
           8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
                    TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
    8.5 OTHER END USERS 
          TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION,  2020–2027 (USD MILLION)
 
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION (Page No. - 92)
    9.1 INTRODUCTION 
          TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
          TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Increasing prevalence of cancer to drive market
                                TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Availability of various cancer screening programs to support market growth
                                TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035
          TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
          TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Government support for research funding to support MRD testing market
                                TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Increasing number of diagnostic laboratories to propel market growth
                                TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Rising R&D expenditure in France to drive market
                                TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Favorable funding scenario to drive market
                                TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Consolidation of laboratories in Spain to support market growth
                                TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
          TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
          TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing public access to advanced healthcare facilities to drive market
                                TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Universal healthcare reimbursement policy to support market growth
                                TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Increasing private and public investments in healthcare system to drive market
                                TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019
                    TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
                    TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                    TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
                    TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,  BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,  BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 124)
     10.1 OVERVIEW 
     10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 
             10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
                        TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021)
             TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 LIST OF EVALUATED VENDORS
             10.5.2 STARS
             10.5.3 EMERGING LEADERS
             10.5.4 PERVASIVE PLAYERS
             10.5.5 PARTICIPANTS
                        FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021) 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
     10.7 COMPETITIVE BENCHMARKING 
             10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
                        FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
                        TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES
                        TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES
                        TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 109 KEY PRODUCT LAUNCHES
             10.8.2 DEALS
                        TABLE 110 KEY DEALS
 
11 COMPANY PROFILES (Page No. - 137)
     11.1 KEY PLAYERS 
(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*
             11.1.1 ADAPTIVE BIOTECHNOLOGIES
                        TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
             11.1.2 ARCHERDX (INVITAE CORPORATION)
                        TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW
                        FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)
             11.1.3 ASURAGEN, INC.
                        TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW
             11.1.4 BIO-RAD LABORATORIES, INC.
                        TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             11.1.5 F. HOFFMANN-LA ROCHE AG
                        TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             11.1.6 GUARDANT HEALTH, INC.
                        TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
                        FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
             11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
                        TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW
                        FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)
             11.1.8 INVIVOSCRIBE, INC.
                        TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
             11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
             11.1.10 NATERA, INC.
                        TABLE 120 NATERA, INC.: BUSINESS OVERVIEW
                        FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)
             11.1.11 SYSMEX CORPORATION
                        TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
     11.2 OTHER PLAYERS 
             11.2.1 NEOGENOMICS LABORATORIES
             11.2.2 OPKO HEALTH, INC.
             11.2.3 GENETRON HEALTH
             11.2.4 QUEST DIAGNOSTICS, INC.
             11.2.5 ARUP LABORATORIES INC.
             11.2.6 MISSION BIO, INC.
             11.2.7 CERGENTIS B.V.
 
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 173)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Minimal Residual Disease Testing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the minimal residual disease testing market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global minimal residual disease testing market Size: Top-Down Approach

Minimal Residual Disease Testing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global minimal residual disease testing market by technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

Minimal residual disease testing market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional five company profiles of players operating in the minimal residual disease testing market.
Report Code
MD 8516
Published ON
Dec, 2022
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Minimal Residual Disease Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback